549505-65-9

ML 3403 is a potent and selective p38 mitogen-activated protein kinase (MAPK) inhibitor. MAPK is a key mediator in cytokine-induced signaling events and plays an integral role in disease states including oncogenesis, autoimmune diseases, and inflammatory processes. Therefore, MAPK inhibitors such as ML 3403 provides an attractive strategy for therapeutic intervention.

Cell permeable: yes''Primary Target
p38 MAP kinase''Product competes with ATP.''Reversible: yes''Target IC50: 0.38 μM for p38α; 0.16 and 0.039 μM in suppressing LPS-induced TNF-α and IL-1β releaserespectivelyin human PBMC; ED50 = 1.33 mg/kg in suppressing LPS-induced TNF-α release in mouse

[1] Kammerer B, et al. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor. Drug Metab Dispos. 2007 Jun;35(6):87 DOI:10.1124/dmd.106.013409